Zobrazeno 1 - 7
of 7
pro vyhledávání: '"A. L. Wappel"'
Publikováno v:
Journal of Cancer Therapy. :907-918
In recent years histone deacetylase inhibitors (HDACi’s) have emerged as promising therapeutics for cancer. While favorable responses to HDACi’s as single agents have been shown in several hematological malignancies, very little efficacy has been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c4e2dfbf384761e2fd32d0763e5a058
https://doi.org/10.4236/jct.2013.44102
https://doi.org/10.4236/jct.2013.44102
Publikováno v:
Journal of Arid Environments. 72:2026-2033
Management of rangelands has changed substantially over the past few decades; today there is greater emphasis on wildlife management and increased interest in using natural disturbances such as fire to manage rangeland plant and animal communities. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a3ace3b9005ee8fb9b51539b7f11204
https://doi.org/10.1016/j.jaridenv.2008.06.002
https://doi.org/10.1016/j.jaridenv.2008.06.002
Publikováno v:
Cell Cycle. 7:1769-1775
ErbB2 targeted therapies represent an attractive strategy in breast cancer. Herceptin, an anti-ErbB2 monoclonal antibody, is an approved treatment for patients with ErbB2-overexpressing breast cancers. ErbB2 signaling can also be blocked using small
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eeb4e500c6e93eb94b3c7aba04beb1a
https://doi.org/10.4161/cc.7.12.6016
https://doi.org/10.4161/cc.7.12.6016
Autor:
Sarah S. Bacus, Scott A. Shell, Robert L. Wappel, Patricia Trusk, Diarmuid M. Moran, Arthur Brown, James Kramer, Dominique R. Talbert, Kimberly R. Doherty
Publikováno v:
Toxicology and applied pharmacology. 272(1)
Tyrosine kinase inhibitors (TKi) have greatly improved the treatment and prognosis of multiple cancer types. However, unexpected cardiotoxicity has arisen in a subset of patients treated with these agents that was not wholly predicted by pre-clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3442c89697ec203a2c7b8d8246513dae
https://pubmed.ncbi.nlm.nih.gov/23707608
https://pubmed.ncbi.nlm.nih.gov/23707608
Autor:
Dominique R. Talbert, Robert L. Wappel, Kimberly R. Doherty, Sarah S. Bacus, Patricia Trusk, Scott A. Shell, Arthur Brown, Diarmuid M. Moran, James W. Kramer
Publikováno v:
Cancer Research. 73:4423-4423
Tyrosine kinase inhibitors (TKi) have greatly improved the treatment and prognosis of multiple cancer types. However, unexpected cardiotoxicity has arisen that was not wholly predicted by current FDA mandated pre-clinical tests. Thus a more robust to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85bad435317304f50dfc2e7b1a3bf6ec
https://doi.org/10.1158/1538-7445.am2013-4423
https://doi.org/10.1158/1538-7445.am2013-4423
Publikováno v:
Cancer Research. 73:3101-3101
In recent years histone deacetylase inhibitors (HDACi's) have emerged as promising therapeutics for cancer. While favorable responses to HDACi's as single agents have been shown in several hematological malignancies, very little efficacy has been dem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::051d95b3dc0d19868e5ca895ba59fbc8
https://doi.org/10.1158/1538-7445.am2013-3101
https://doi.org/10.1158/1538-7445.am2013-3101
Publikováno v:
Molecular Cancer Therapeutics. 8:A259-A259
Background: Targeted cancer therapies can elicit undesired physiological effects including cardiac toxicity which may result from the inhibition of an oncogenic protein that is also required for normal heart health, such as c-Abl by Imatinib or HER2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da99baa6c2bb8a09f3ad0d685cf0de3f
https://doi.org/10.1158/1535-7163.targ-09-a259
https://doi.org/10.1158/1535-7163.targ-09-a259